ProMetic raises $30 million

Canada's ProMetic Life Sciences has raised $30 million in debt financing from Structured Alpha LP, an affiliate of Peter J. Thomson's investment firm, Thomvest Asset Management. Thomson's investment firm has now invested $60 million in ProMetic. The biotech offers a range of services, including large-scale purification of biologics, drug development, proteomics and the elimination of pathogens. Release

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.